Novel adeno-associated virus-based genetic vaccines encoding hepatitis C virus E2 glycoprotein elicit humoral immune responses in mice

FENGQIN ZHU, YIBO WANG, ZHEN XU, HAIYANG QU, HAIRONG ZHANG, LINGLING NIU, HONGLU XUE, DEHUAI JING and HENG HE

Department of Gastroenterology, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong 272000, P.R. China

Received April 23, 2018; Accepted November 20, 2018

DOI: 10.3892/mmr.2018.9739

Abstract. Hepatitis C virus (HCV) infection remains a major public health issue despite the introduction of several direct-acting antiviral agents (DAAs), with some 185 million individuals infected with HCV worldwide. There is an urgent need for an effective prophylactic HCV vaccine. In the present study, we constructed genetic vaccines based on novel recombinant adeno-associated viral (rAAV) vectors (AAV2/8 or AAV2/rh32.33) that express the envelope glycoprotein E2 from the HCV genotype 1b. Expression of HCV E2 protein in 293 cells was confirmed by western blot analysis. rAAV2/8.HCV E2 vaccine or rAAV2/rh32.33.HCV E2 vaccine was intramuscularly injected into C57BL/6 mice. HCV E2-specific antigen was produced, and long-lasting specific antibody responses remained detectable XVI weeks following immunization. In addition, the rAAV2/rh32.33 vaccine induced higher antigen-specific antibody levels than the rAAV2/8 vaccine or AAV plasmid. Moreover, both AAV vaccines induced neutralizing antibodies against HCV genotypes 1a and 1b. Finally, it is worth mentioning that neutralizing antibody levels directed against AAV2/rh32.33 were lower than those against AAV2/8 in both mouse and human serum. These results demonstrate that AAV vectors, especially the AAVrh32.33, have particularly favorable immunogenicity for development into an effective HCV vaccine.

Introduction

Hepatitis C virus (HCV) infects approximately 185 million people worldwide and is a leading cause of liver cirrhosis and hepatocellular carcinoma (1). Yet, no effective HCV vaccine is available. Although the introduction of new direct-acting antiviral agents (DAAs) is highly effective in the treatment of all HCV genotype infections, their use is limited by high cost, treatment accessibility and potential drug resistance (2). Furthermore, patients cured following DAA use are susceptible to reinfection (3). Therefore, an effective prophylactic vaccine is necessary to protect against HCV infection.

HCV, a positive-stranded RNA virus, exists as seven major genotypes and numerous subtypes. However, the high genetic variability of the HCV genome presents many challenges for vaccine development (4). Previous studies have shown that the T-cell immune response plays a crucial role in HCV clearance (5,6). It is now known that timely production of cross-neutralizing antibodies (NAbs) are associated with viral resolution (7).

HCV envelope glycoproteins E1 and E2 form a heterodimer on the surface of HCV. Various types of E1E2-based vaccine candidates have been tested. However, a phase I study with recombinant HCV E1/E2 envelope glycoprotein as a candidate vaccine did not induce a strong immune response in volunteers (8,9). E2, the larger one of the two envelope proteins, interacts directly with cellular receptors CD81 and scavenger receptor class B member 1 (SR-B1) to mediate viral entry (10). E2 is an optimal antigen candidate for HCV vaccination because it possesses most NAb-recognized epitopes (11-13). To date, a number of HCV vaccine candidates based on E2 have been explored. A DNA vaccine encoding HCV E2 has been shown to induce specific antibody responses in mice (14). Prime-boost immunization with the virus-like particles (VLPs) containing E2, E1, or both elicited NAbs in non-human primates (15). A subunit vaccine based on soluble E2 (sE2) of the Con1 strain (GT1b) induces NAbs in mice and rhesus monkeys (16,17). A recent study also demonstrated that a trivalent HCV vaccine containing sE2 from genotypes 1a, 1b and 3a elicited a broad, synergistic polyclonal antibody response in mice and rhesus monkeys (18).

Viral vector vaccines have been demonstrated to induce strong cellular and humoral immune responses. A variety of viral vectors, such as adenovirus, poxvirus and measles, have been tested as platforms for HCV vaccination (19,20).
In recent years, the adeno-associated virus (AAV) vector, a single-stranded DNA virus from the Paroviridae family, has emerged as an attractive agent for vaccine development owing to its long-term persistence, high efficiency, low immunogenicity and lack of pathogenicity in gene delivery studies. Moreover, AAVs are also able to infect both non-dividing and dividing cells in the liver, muscle and brain (21-23). A remarkable feature of AAV vector vaccines is their capacity to induce strong and long-lasting antibody responses. Several studies have documented that the induction of humoral responses could last for many months (24-27). Such prominent antibody response may be relevant to the high and sustained expression of the immunogen by most AAV serotypes (27-29).

AAV8 has shown remarkable potential as a gene delivery vector in vivo (30). AAVrh32.33, a novel vector isolated from rhesus macaques, has relatively low seroprevalence in humans compared to AAV2 and AAV8 (31,32). Genetic vaccines based on AAV8 and AAVrh32.33 vectors encoding truncated dengue virus envelope proteins have been shown to elicit a long-lasting humoral responses in mice (33).

Previously, we constructed an HCV vaccine based on AAVrh32.33 expressing NS3/4 protein, which exhibits immunogenic properties superior to those of an NS3-protein-based vaccine in C57BL/6 mice (34). In the present study, we continued to focus on AAV vectors and generated AAV2/8 and AAV2/rh32.33 vectors expressing HCV E2 protein. After purification and titration of the two recombinant vectors, we evaluated their humoral immunity induced in C57BL/6 mice.

**Materials and methods**

**Plasmid construction.** Serum samples of HCV GT1b were collected from six patients (four females and two males, aged 30-50 years) diagnosed at the Affiliated Hospital of Jining Medical University (Shandong, China) between April and August 2017 after obtaining written informed consent from the HCV-infected patients. The study was approved by the Ethics Committee of Jining Medical University. Total RNA was obtained using a viral RNA Mini kit (Qiagen, Duesseldorf, Germany) according to the manufacturer’s protocol. cDNA was synthesized using the PrimeScript II First-Strand cDNA Synthesis kit (Takara Bio Inc., Tokyo, Japan). Next, the HCV E2 gene was amplified by PCR with Pyrobest DNA polymerase (Takara Bio Inc.) and specific primer. Two primer sequences were used: forward, 5'-GGA AGA TCT CGC CGC CAC CAT GGT TGGGGA CTG GGC-3' and reverse, 5'-GTCTA GCG CCAT TA AACT CAG CC TCG CTT GGGA T3. NorI and BglII sites were used to clone the ampiclons into the AAV cis-plasmid (a kind gift from Dr Wilson, Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA). The identification of AAV recombinants was confirmed by restriction enzyme digestion and sequencing. The recombinant plasmid was named pAAVCMV.HCV.E2.

**Detection of HCV E2 expression in 293 cells.** 293 cells were plated at a density of 1x10⁶ cells in a 6-well plate with Dulbecco's modified Eagle's medium (DMEM; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.) and then incubated at 37°C in a 5% CO₂ incubator. After 24 h, they were transfected with 4 mg AAV plasmids encoding eGFP (pAAV.CMV.eGFP) or HCV E2 (pAAV.CMV.HCV.E2) by Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) following the manufacturer's instructions. Seventy-two hours after the transfection, eGFP gene expression was confirmed using a direct fluorescence microscopy (Micro Publisher 3.3 RTV; Olympus Corp., Tokyo, Japan) and HCV E2 gene expression was detected by western blot analysis. The transfected cells were harvested and lysed as samples. After separation using 10% sodium dodecyl-sulfate polyacrylamide gel electrophoresis gels (SDS-PAGE), samples were transferred onto a polyvinylidene difluoride (PVDF) membrane. The membrane was blocked for 2 h with 5% non-fat milk, incubated overnight at 4°C with an anti-HCV E2 monoclonal antibody (cat. no. 1876-E2; 1:100; Virostat; Bio-Lab Laboratories Ltd., Beijing, China), washed three times in Tris-buffered saline with Tween-20 (TBST), and then incubated with the horseradish peroxidase (HRP)-conjugated goat anti-mouse secondary antibody (cat. no. ab6789; 1:10,000; Abcam, Cambridge, MA, USA) for 1 h at room temperature. Finally, protein expression was visualized using Pierce ECL Western Blotting substrate (Pierce Biotechnology, Inc.; Thermo Fisher Scientific, Inc.), quantified using densitometry, and analyzed using Gel-Pro software version 3.2 (Media Cybernetics, Inc., Rockville, MD, USA). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used an internal control in western blot analyses.

**Production of rAAV vectors.** All rAAV vectors were packaged by triple plasmid transfection in 293 cells, as previously described (35,36). The triple plasmid system is comprised of an AAV cis-plasmid containing HCV E2 cDNA (pAAV.CMV.HCV.E2), an adenovirus helper plasmid (pAd.F6), and a chimeric packaging plasmid that contains the AAV2 rep gene and the AAV8 (or AAVrh32.33) cap gene (pAAV2/8 or pAAV2/rh32.33). All plasmids were extracted using a Plasmid Maxi kit (Qiagen) following the manufacturer's instructions. Briefly, 2 h before transfection, at the point when the 293 cells were cultured in 15-cm culture dishes reaching high confluence (70-80%), they were treated with 20 ml DMEM supplemented with 10% FBS without antibiotics. Equimolar plasmids were dissolved in 650 µl of CaCl₂ (2.5 M) and 5.9 ml of Milli-Q water, then mixed rapidly with 12.5 ml of 2X 4-(2-hydroxyethyl)-1-piperazinethanesulfonic acid-buffered saline (pH 7.05) to prepare the transfection solution. A 2.5 ml aliquot of the above transfection solution was gently added to each dish. After slowly swirling the contents to mix, the cells were incubated at 37°C in a 5% CO₂ incubator continuously. At 16 h post-transfection, the medium was replaced with fresh DMEM containing 10% FBS and 100 mg/ml streptomycin and penicillin. Another 72 h after medium replacement [at which time eGFP signals were visualized as distinctly shaped foci on fluorescence microscopy (Thermo Fisher Scientific, Inc.)], cells were collected and resuspended with 10 ml of NaCl (150 mM) and Tris (20 mM, pH 8.0). Next, benzozene nuclease (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) was added to a final concentration of 50 U/ml to remove nucleic acid contamination. rAAV was obtained from lysed 293 cells by means of three consecutive freeze-thaw-cycles (-80°C and
37°C). The rAAV vectors were purified by three rounds of cesium chloride gradient centrifugation, and then concentrated using Amicon Ultra-15 centrifugal filter devices (100K; Merck Millipore, Billerica, MA, USA). The AAV genome titers [genome copies (GC) per ml] were detected by real-time PCR using Premix Ex Taq (Takara Bio Inc.) corresponding to the polyA region of the AAV vector.

**Immunization of mice.** All animal procedures were performed in accordance with the protocols approved by the Ethics Committee of Jining Medical University. Female C57BL/6 mice (4-6 weeks of age, weight 15.00±0.31 g) were purchased from SLAC Laboratory Animal Company (Shanghai, China) and housed at a constant temperature with a 12 h dark/light cycle. Food and water were available ad libitum. The mice were randomly divided into 4 groups of 10 mice each. After being anesthetized by inhalation of 1.5% isoflurane in oxygen, two groups of mice were immunized intramuscularly (tibialis anterior muscle of the hind leg) with rAAV2/8.HCV E2 vaccine or rAAV2/rh32.33.HCV E2 vaccine (1x10^11 GC per mouse). The other two groups were immunized with pAAV.CMV.HCV.E2 plasmid (100 µg per mouse) or phosphate-buffered saline (PBS) (100 µl per mouse) as controls. At weeks 12 and 16 post-immunization, two mice in each group were sacrificed by inhalant isoflurane overdose (1.5%), for skeletal muscle harvesting from the vaccine injection area. The tissue samples were stored at -80°C for subsequent western blot analysis. Blood samples of mice were collected via retro-orbital puncture under anesthesia as above at weeks 0, 4, 8, 12 and 16 post-immunization and stored at -20°C.

**Evaluation of HCV E2-specific antibody reactivity.** To measure HCV E2-specific antibody reactivity, mouse sera were evaluated by enzyme-linked immunosorbent assay (ELISA). Briefly, 96-well plates were coated with GST-E2 peptide and incubated overnight at 4°C. Plates were then washed with phosphate-buffered solution (PBST) and blocked with 1% bovine serum albumin (BSA) for 2 h at room temperature. A 1:1,000 dilution anti-mouse IgG HRP-conjugated antibody (cat. no. A5278; Sigma-Aldrich; Merck KGaA) was used as a secondary antibody. Mouse serum samples were diluted to 1:2 and 1:20 for ELISA analysis. After washing with PBST, 3,3',5,5'-tetramethylbenzidine (Invitrogen; Thermo Fisher Scientific, Shanghai, China) was added to each well. Finally, the plates were read at a wavelength of 450 nm (OD_{450}; ELx800; BioTek Instruments, Inc., Winooski, VT, USA). IgG titers are presented as the reciprocal of the highest serum dilution at which the OD_{450} nm was higher than twice that of the control.

**Evaluation of neutralizing antibody response to hepatitis C virus.** To evaluate the neutralizing ability of HCV-specific antibodies, infectious pseudo-particles expressing HCV envelope glycoproteins (HCVpp) with E2 protein of five genotypes [1a (H77), 1b (Hebei), 2a (JFH1), 3a (S52) and 5a (SA13)] were produced to evaluate NAb induction (37,38). After purification in a protein G column, serum samples were serially diluted and incubated with HCVpp for 1 h at 37°C, at which time the mixtures were used to infect HuH7.5 cells. After 48 h, luciferase activity in the infected HuH7.5 cells was detected with a Bright-Glo luciferase assay (Promega, Madison, WI, USA).

Data were reported as relative luminescence units. The positive control, AP33, is a monoclonal anti-E2 antibody with broad cross-neutralization ability. Neutralizing capacity was evaluated by comparing the luciferase activity in cells infected with HCVpp that had been incubated with serum from vaccinated animals to those that had been incubated with pre-vaccinated serum from the same mice.

**Evaluation of neutralizing antibody response against the AAV vector.** Serum samples collected from 20 naive mice and 20 humans were diluted to determine anti-AAV2/rh32.33 and -AAV2/8 vector NAb levels. Briefly, serum samples were inactivated at 56°C for 35 min. The AAAY2/8.CMV.eGFP and AAV2/rh32.33.CMV.eGFP vectors were diluted in serum-free DMEM and incubated with serial dilutions (1:20 and 1:80) of serum samples at 37°C for 1 h. Next, 100 µl of the serum-vector mixture was added to the 293 cells that had been infected 2 h earlier with wild-type adenovirus 5. After incubation at 37°C under 5% CO₂ for 24 h, eGFP protein expression was evaluated for each group with fluorescence microscopy (Thermo Fisher Scientific, Inc.). NAb titer was determined as the highest serum dilution that inhibited AAV transduction (eGFP expression) by 50%, relative to the mouse serum control.

**Statistical analysis.** Mean values are reported with standard deviations (SDs). GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA, USA) and SPSS software (version 17.0; SPSS, Inc., Chicago, IL, USA) were used for statistical analyses. Differences between groups were examined by Student's t-test for two groups and one-way analysis of variance (ANOVA) followed by a least significant difference test for multiple comparisons. A P-value of <0.05 was considered statistically significant.

**Results**

**Expression of the AAV plasmid encoding the HCV E2 gene in vitro.** In vitro expression of HCV E2 protein was evaluated by western blot analysis in recombinant AAV plasmid-transfected 293 cell lysates 72 h after transfection. 293 cells transfected with pAAV.CMV.HCV E2 plasmid had a band of ~70 kDa, whereas those transfected with pAAV.CMV.eGFP had no detectable band (Fig. 1).

**Comparison of HCV E2 expression among the different vaccines.** The rAAV final yield ranged from 5.53x10^{11} GC to 1.02x10^{12} GC. HCV E2 expression was compared between HepG2 cells infected with rAAV2/8.HCV E2 vaccine or rAAV2/rh32.33.HCV E2 vaccine, respectively (MOI=3x10^4 GC). HepG2 cells transfected with pAAV.CMV.HCV.E2 plasmid or pAAV.CMV.eGFP plasmid served as positive and negative controls, respectively. After 72 h, the 70-kDa antigen was effectively expressed in cell lysates (data not shown). Western blot analysis of E2 expression in injection-area skeletal muscle (2 mice/group) and the two rAAV vaccines (AAV2/rh32.33 and AAV2/8) expressed HCV E2 protein in immunized mice for at least 16 weeks post-immunization (Fig. 2). In addition, the HCV E2 expression level did not differ between the rAAV and the AAV plasmid.
Thus, NAb titers to AAV2 inhibited >50%, which is more than that observed for the eGFP protein expression levels in the AAV2 vectors. The NAb titer was determined as the highest serum dilution that inhibited AAV transduction (eGFP expression) by 50% compared to mouse control serum. As shown in Fig. 4, both AAV vaccines demonstrated significant neutralization of HCVpp derived from HCV genotypes 1a and 1b at week 12.

Neutralizing antibody against AAV in human and mouse sera. To evaluate the NAb titers were determined as the highest serum dilution that inhibited AAV transduction (eGFP expression) by 50% compared to mouse control serum. As shown in Fig. 5, the eGFP protein expression levels in the AAV2/8 group were inhibited >50%, which is more than that observed for the AAV2/rh32.33 group both at serum dilutions of 1:20 and 1:80. Thus, NAb titers to AAV2/rh32.3 were lower than NAb titers to AAV2/8.

Discussion

There are many obstacles to develop a prophylactic hepatitis C virus (HCV) vaccine, such as the extensive variability of the HCV genome and the absence of a suitable small animal model. However, several candidate HCV vaccines have been created, including DNA vaccines, recombinant viral vectors, proteins and virus-like particles (VLPs) (39,40). Vector comparison is valuable to illustrate factors influencing vaccine immunogenicity and to improve genetic vaccination.

HCV vaccines based on recombinant viral vectors have generated promising results in preclinical experiments. To date, four vector vaccines have been able to induce T-cell and B-cell responses in rhesus macaques in prime-boost regimens: DNA, SFV, human serotype 5 adenovirus (HuAd5) and modified vaccinia ankara (MVA) poxvirus expressing HCV core, E1, E2 and NS3 (41). Simian adenoviral vaccine vectors (ChAdOx) encoding genetically conserved gene segments from HCV primed broad, cross-reactive T-cell responses successfully in C57BL/6 mice (42). Relative to these commonly used viral vectors, rAAV vectors have potential advantages for vaccine and gene transfer applications owing to their lower inflammatory potential, availability of viral serotypes with different tissue tropisms, and possible long-lasting gene expression. Additionally, AAV-based genetic vaccines encoding the antigen genes of interest can elicit both humoral and cellular immune responses to the transgene. A genetic HIV vaccine based on AAV vectors induced anti-HIV T-cell responses in mice (43). The use of AAV vectors for delivery of broadly neutralizing HIV antibodies could stimulate long-term, systemic broadly neutralizing antibody in the absence of immunization to prevent HIV infection (28). However, AAV vaccines have been limited by factors such as high sero-prevalence in humans. To date, more than 120 AAV serotypes and variants have been identified; several serotypes, such as AAV8 and AAVrh32.33, show high transduction efficiency but low sero-prevalence (44). Genetic vaccines based on AAV8 and AAVrh32.33 vectors encoding truncated dengue virus envelope proteins have been shown to elicit long-lasting humoral responses in mice (33). Hence, we chose AAV8 and AAVrh32.33 vectors to create HCV vaccines and compared their immunogenicity in C57BL/6 mice by intramuscular injection.
The present study is the first study to show that AA V vectors can express HCV E2 antigen and induce humoral immune responses in mice. In this study, both AA V vaccines produced high absolute levels of HCV E2 antigen in mice. Antigen synthesis lasted for several weeks, and the synthesized antigen provided continuous stimulation to the mouse immune system. However, the HCV E2 expression level did not differ between the rAA V and the DNA. There are a few possible explanations for this finding. Firstly, our AA V vaccine was of low purity and quality. Secondly, the small sample size of immunized mice may have underpowered the study to detect a true difference. We will conduct further experiments to clarify whether a difference does exist. Furthermore, the HCV E2-specific antibody assay showed that the AAV2/rh32.33-based HCV vaccine induced higher levels of E2-specific antibodies than did the AAV2/8 vaccine. Thus, the AAV2/rh32.33-based HCV vaccine appears to possess superior immunogenic properties compared to the AAV2/8-based vaccine. Moreover, there were fewer NAb s to AA Vrh32.33 than to AA V8 in mice and human sera, indicating that AA Vrh32.33 may be safer than AA V8.

Previously, we developed HCV vaccines based on an AA Vrh32.33 vector expressing HCV NS3 or NS3/4b that could elicit strong and persistent T-cell immunity in mice (34). Moreover, there have been studies indicating that an AA Vrh32.33 vector encoding antigens of HIV-1 would stimulate stronger immune responses than an AA V8 vector in non-human primates (31). Above all, we speculate that, beyond safety, AA Vrh32.33 could stimulate potent transgene production more efficiently. Thus, AA V vectors, especially AA Vrh32.33, are attractive potential vectors for HCV vaccine design.

Since humoral immunity and NAbs play a pivotal role in HCV clearance, the identification of conserved epitopes associated with viral neutralization is a crucial factor in the development of an effective prophylactic HCV vaccine. The envelop glycoprotein E2 is the primary target of the anti-HCV NAb response. In past decades, several studies have helped to elucidate the structural features of HCV glycoprotein E2, showing that key epitopes targeted by NAbs on the ‘front layer’ of E2 exhibit structural heterogeneity. Thus, E2 appears to be an ideal antigen candidate for HCV vaccine design (45,46).

In this study, we developed HCV vaccines based on AA V vectors expressing E2 protein from GT1b, which is the
predominant genotype in the Chinese population, accounting for 56.8% (47). Firstly, we investigated and compared HCV E2 protein expression levels for three different designs. Western blot analysis showed that all constructs produced the 70-kDa E2 protein. We then determined that AAV vaccines encoding HCV E2 could induce high-level production of HCV E2-specific antibodies and NAbs in C57BL/6 mice. Additionally, cross protection against genotypes 1a and 1b were superior to that directed against genotypes 2a, 3a and 5a HCVpp. Our finding is consistent with that of previous research showing that genotype 1 antigen induced weaker neutralization against HCV genotypes 2, 3 and 5 than genotype 1 (48). However, efficient T-cell responses were not detected in immunized mice in this study (data not shown). One possible explanation is that T-cell-specific epitopes are not properly exposed in whole HCV E2 protein. Therefore, further exploration of truncated E2 proteins possessing T-cell-specific epitopes is needed.

In conclusion, we constructed novel AAV-based vaccines encoding E2 protein directed against HCV and confirmed their ability to elicit E2-specific antibody and NAb responses in C57BL/6 mice. We plan to further evaluate the immunity generated by AAV vaccines in immune-competent humanized mice. Moreover, we will explore other optimal antigens to induce both humoral and cell responses against HCV, with the goal of developing an efficient prophylactic HCV vaccine.

Acknowledgements
Not applicable.

Funding
The present study was supported by the Natural Science Foundation of Shandong Province, China (grant no. ZR2017LH009) and the PhD Research Startup Foundation of the Affiliated Hospital of Jining Medical University (grant no. 2016-BS-015).

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Authors' contributions
HH and FZ designed the study. FZ, YW, ZX, HQ, HZ, LN, HX and DJ performed the experiments. YW, ZX, HQ, HZ, LN, HX and DJ analyzed the data. FZ prepared the manuscript. HH revised the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
All patients provided written informed consent to participate. All experimental procedures performed with human and mice...
were approved by the Ethics Committee of Jining Medical University (Shandong, China).

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References

1. Li D, Huang Z and Zhong J: Hepatitis C virus vaccine development: Old challenges and new opportunities. Natl Sci Rev 28: 285-295, 2015.

2. Pawlotsky JM: Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology 151: 70-86, 2016.

3. Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanen T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, et al.: Daclatasvir plus sofosbuvir for previously untreated chronic Hep C virus infection: Consensus of concomitant immunity in mice. J Virol 90: 10486-10498, 2016.

4. Li D, Wang X, von Schawaen M, Tao W, Zhang Y, Li L, Heller B, Hrebikova G, Deng Q, Ploss A, et al.: Altered glycosylation patterns increase immunogenicity of a subunit hepatitis C virus vaccine, inducing neutralizing antibodies which confer protection in mice. J Virol 90: 10486-10498, 2016.

5. Li D, Wang X, von Schawaen M, Tao W, Zhang Y, Heller B, Hrebikova G, Deng Q, Sun Q, Ploss A, et al.: Immunization with a subunit hepatitis C virus vaccine elicits pan-genotypic neutralizing antibodies and intrahepatic T-cell responses in nonhuman primates. J Infect Dis 215: 1824-1831, 2017.

6. Wang X, Yan Y, Gan T, Yang X, Li D, Zhou D, Sun Q, Huang Z and Zhong J: A trivalent HCV vaccine elicits broad and synergistic polyclonal antibody response in mice and rhesus monkey. Gut: Nov 27, 2017 (Epub ahead of print).

7. Draper SJ and Heeney JL: Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 8: 62-73, 2010.

8. Guo J, Mondal M and Zhou D: Development of novel vaccine vectors: Chimpanzee adeno viral vectors. Hum Vaccin Immunother 14: 1679-1685, 2018.

9. Mak KY, Rajapaksha IG, Angus PW and Herath CB: The adeno-associated virus-A safe and promising vehicle for liver-specific gene therapy of inherited and non-inherited disorders. Curr Gene Ther 17: 4-16, 2017.

10. Guo J, Zhai H, Li X, Ma L, Chen B, Liu F, Lai H, Xie J, He C, Luo J, et al.: Recombinant adeno-associated virus serotype 9 in a mouse model of atherosclerosis: Determination of the optimal expression time in vivo. Mol Med Rep 15: 2090-2096, 2017.

11. Cabral-Miranda F, Nicrolo-Simões E, Adão-Novaes J, Chiodo V, Hauswirth WW, Linden R, Chiariini LB and Pets-Silva H: AAV-7418-7422-mediated gene transfer of CHIP/Stub-1 prevents hippocampal neuronal death in experimental brain ischemia. Mol Ther 25: 392-400, 2017.

12. Manning WC, Paliard X, Zhou S, Pat Bland M, Lee AY, Hong K, Walker CM, Escobedo JA and Dwaraki V: Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D. J Virol 71: 7960-7962, 1997.

13. Kuck D, Lau T, Leuchs B, Kern A, Müller M, Gissmann L and Kleinschmidt JA: Intra nasal vaccination with recombinant adeno-associated viruses type 5 against human papillomavirus type 16. J Virol 80: 2621-2630, 2006.

14. Nieto K, Kern A, Leuchs B, Gissmann L, Müller M and Kleinschmidt JA: Combined prophylactic and therapeutic intranasal vaccination against human papillomavirus type 16 using different adeno-associated virus serotype vectors. Antivir Ther 14: 1125-1137, 2009.

15. Pollquin A, Szecsi J, Mathieu C, Guillaume V, Barateau V, Ong KC, Wong KT, Cossset FL, Horvat B and Salvetti A: Protection against henipavirus infection by use of recombinant adeno-associated virus vectors. J Infect Dis 207: 469-478, 2013.

16. Lin J, Zhi Y, Mays L and Wilson JM: Vaccines based on novel adeno-associated virus vectors elicit aberrant CD8+ T-cell responses in mice. J Virol 81: 11840-11849, 2007.

17. Lin SW, Hensley SE, Tatsis N, Lasaoro MO and Ertl HC: Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice. J Clin Invest 117: 3958-3970, 2007.

18. Qiu Y, Tao L, Zheng S, Lin R, Fu X, Chen Z, Li X, Xiong, Ploss A, et al.: Identification of a novel epitope in the C terminus of hepatitis C virus E2 protein that induces potent and cross-reactive neutralizing antibodies. J Gen Virol 98: 962-976, 2017.

19. T-detesci V, Atsuka T, Shih JW, Battegay M and Feinstein SM: A specific antibody response to HCV E2 elicited in mice by intramuscular inoculation of plasmid DNA containing coding sequences for E2. Hepatology 25: 459-462, 1997.

20. Garene P, Fluckiger AC, Mangeot PE, Gauthier T, Dupuyret-Lacat P, Mancip J, Cangialosi A, Du Chéné I, LeGrand R, Mangeot I, et al.: A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci Transl Med 3: 94ra71, 2011.
35. Xiao X, Li J and Samulski RJ: Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 72: 2224-2232, 1998.
36. Wang L, Calcedo R, Nichols TC, Bellingar DA, Dillow A, Verma IM and Wilson JM: Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy. Blood 105: 3079-3786, 2005.
37. Drex M and Cosset FL: Detection of neutralizing antibodies with HCV pseudoparticles (HCVpp). Methods Mol Biol 510: 427-438, 2009.
38. Guan J, Wen B, Deng Y, Zhang K, Chen H, Wu X, Ruan L and Tan W: Effect of route of delivery on heterologous protection against HCV induced by an adenovirus vector carrying HCV structural genes. Virol J 8: 506, 2011.
39. Roohvand F and Kossari N: Advances in hepatitis C virus vaccines, part two: Advances in hepatitis C virus vaccine formulations and modalities. Expert Opin Ther Pat 22: 391-415, 2012.
40. Liang TJ: Current progress in development of hepatitis C virus vaccines. Nat Med 19: 869-878, 2013.
41. Rollier CS, Verschoor EJ, Verstrepen BE, Drexhage JA, Paranjos-Baccala G, Liljestrom P, Sutter G, Arribilaga L, Lasarte JJ, Bartosch B, et al: T- and B-cell responses to multivalent prime-boost DNA and viral vectored vaccine combinations against hepatitis C virus in non-human primates. Gene Ther 23: 753-759, 2016.
42. von Delft A, Donnison TA, Lourenço J, Hutchings C, Mullarkey CE, Brown A, Pybus OG, Klenerman P, Chinnakannan S and Barnes E: The generation of a simian adeno-viral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes. Vaccine 36: 313-321, 2018.
43. Brady JM, Baltimore D and Balazs AB: Antibody gene transfer with adeno-associated viral vectors as a method for HIV prevention. Immunol Rev 275: 324-333, 2017.
44. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J and Wilson JM: Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 99: 11854-11859, 2002.
45. Meola A, Tarr AW, England P, Meredith LW, McClure CP, Foug SK, McKeating JA, Ball JK, Rey FA and Krey T: Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies. J Virol 89: 2170-2181, 2015.
46. Vasiliauskaite I, Owsianka A, England P, Khan AG, Cole S, Bankwitz D, Foug SKH, Pietschmann T, Marcotrigiano J, Rey FA, et al: Conformational flexibility in the immunoglobulin-like domain of the hepatitis C virus glycoprotein E2. MBio 8: e00382-17, 2017.
47. Yuan G, Liu J, Hu C, Huang H, Qi M, Wu T, Liang W, Li YP, Zhang YY and Zhou Y: Genotype distribution and molecular epidemiology of hepatitis C virus in Guangzhou, China: Predominance of genotype 1b and increasing incidence of genotype 6a. Cell Physiol Biochem 43: 775-787, 2017.
48. Law JL, Chen C, Wong J, Hockman D, Santer DM, Frey SE, Belshe RB, Wakita T, Bukh J, Jones CT, et al: A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans. PLoS One 8: e59776, 2013.